Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16367362 | 1.00 | L3MBTL1 (0.37) | L3MBTL1ALDH1A1PKMTAAR1HIF1A | |
| SCHEMBL15607806 | 0.93 | L3MBTL1 (0.40) | L3MBTL1ALDH1A1PKMTAAR1HIF1A | |
| SCHEMBL16367312 | 0.89 | ALDH1A1 (0.39) | L3MBTL1ALDH1A1PKMTAAR1HIF1A | |
| SCHEMBL16367294 | 0.89 | ALDH1A1 (0.39) | L3MBTL1ALDH1A1PKMTAAR1HIF1A | |
| SCHEMBL16367299 | 0.89 | ALDH1A1 (0.39) | L3MBTL1ALDH1A1PKMTAAR1HIF1A | |
| SCHEMBL15607817 | 0.87 | L3MBTL1 (0.36) | L3MBTL1ALDH1A1PKMTAAR1HIF1A | |
| SCHEMBL15544866 | 0.84 | L3MBTL1 (0.39) | L3MBTL1ALDH1A1PKMTAAR1HIF1A | |
| SCHEMBL16367295 | 0.83 | ALDH1A1 (0.42) | L3MBTL1ALDH1A1PKMTAAR1HIF1A | |
| SCHEMBL16367422 | 0.83 | ALDH1A1 (0.38) | L3MBTL1ALDH1A1PKMTAAR1HIF1A | |
| SCHEMBL16342941 | 0.83 | ALDH1A1 (0.38) | L3MBTL1ALDH1A1PKMTAAR1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
| EP-2793871-A1 | COMPOUNDS AND METHODS FOR SELECTIVE IMAGING AND/OR ABLATION | Auckland Uniservices Limited (NZ) | 2014-10-29 | — | — | EP | disclosed |
| WO-2014007650-A1 | COMPOUNDS AND METHODS FOR SELECTIVE IMAGING AND/OR ABLATION | AUCKLAND UNISERVICES LIMITED (NZ) | 2014-01-09 | — | — | WO | disclosed |
| WO-2014007650-A1 | COMPOUNDS AND METHODS FOR SELECTIVE IMAGING AND/OR ABLATION | AUCKLAND UNISERVICES LIMITED (NZ) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | CBR1, CBR3, BLVRB | L3MBTL1 2029/4885ALDH1A1 140/4885PKM 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.